The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer

Archives of Otolaryngology - Head and Neck Surgery

Volumn 133, Issue 3, 2007, Pages 281-288

  Wang, Steven J ^a,b   Peyrollier, Karine ^a   Bourguignon, Lilly Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; HERMES ANTIGEN; HYALURONIC ACID; PHOSPHOLIPASE C; PROTEIN KINASE (CALCIUM,CALMODULIN) II;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; ENZYME ACTIVITY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; SQUAMOUS CELL CARCINOMA;

ANTIGENS, CD44; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CALCIUM SIGNALING; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; ETOPOSIDE; HEAD AND NECK NEOPLASMS; HUMANS; HYALURONIC ACID; MALE; PHOSPHOLIPASE C; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 33947374341     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.133.3.281     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Toole BP, Hascall VC. Hyaluronan and tumor growth. Am J Pathol. 2002;161:745-747.
3. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem. 2002;277:4589-4592.
4. Carinci F, Stabellini G, Calvitti M, et al. CD44 as prognostic factor in oral and oropharyngeal squamous cell carcinoma. J Craniofac Surg. 2002;13:85-89.
5. Bourguignon LY. CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. J Mammary Gland Biol Neoplasia. 2001;6:287-297.
6. Bourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA, Hung MC. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185HER2 and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem. 2001;276:48679-48692.
7. Franzmann EJ, Weed DT, Civantos FJ, Goodwin WJ, Bourguignon LY. A novel CD44 v3 isoform is involved in head and neck squamous cell carcinoma progression. Otolaryngol Head Neck Surg. 2001;124:426-432.
8. Wang SJ, Bourguignon LY. Hyaluronan promotes CD44-epidermal growth factor receptor interaction, oncogenic signaling, and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006;132:771-778.
9. 2+ signaling during hyaluronan (HA)-induced endothelial cell migration. Cell Motil Cytoskeleton. 2002;53:293-316.
10. 2+ signaling leading to nitric oxide production and endothelial cell adhesion and proliferation. Exp Cell Res. 2004;295:102-118.
11. 2+ signaling, and cortactin-cytoskeleton function leading to keratinocyte adhesion and differentiation. J Biol Chem. 2004;279:29654-29669.
12. Thomas SM, Coppelli FM, Wells A, et al. Epidermal growth factor receptor-stimulated activation of phospholipase C-gamma-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Res. 2003;63:5629-5635.
13. Kokoska ER, Wolff AB, Smith GS, Miller TA. Epidermal growth factor-induced cytoprotection in human intestinal cells involves intracellular calcium signaling. J Surg Res. 2000;88:97-103.
14. 2+ signaling and cisplatin resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006;132:19-24.
15. 2+/calmodulin-dependent protein kinase inhibitor KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenyl piperazine) in small cell lung carcinoma. Biochem Pharmacol. 1996;51:707-715.
16. 2+/calmodulin-dependent protein kinase inhibitor KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine). Biochem Pharmacol. 1995;50:1979-1985.
17. Yang BF, Xiao C, Roa WH, Krammer PH, Hao C. Calcium/calmodulin-dependent protein kinase II regulation of c-FLIP expression and phosphorylation in modulation of Fas-mediated signaling in malignant glioma cells. J Biol Chem. 2003;278:7043-7050.
18. Illario M, Cavallo AL, Monaco S, et al. Fibronectin-induced proliferation in thyroid cells is mediated by alphavbeta3 integrin through Ras/Raf-1/MEK/ERK and calcium/CaMKII signals. J Clin Endocrinol Metab. 2005;90:2865-2873.
19. Leppard JB, Champoux JJ. Human DNA topoisomerase I: relaxation, roles, and damage control. Chromosoma. 2005;114:75-85.
20. Porter AC, Farr CJ. Topoisomerase II: untangling its contribution at the centromere. Chromosome Res. 2004;12:569-583.
21. Wells NJ, Fry AM, Guano F, Norbury C, Hickson ID. Cell cycle phase-specific phosphorylation of human topoisomerase II alpha: evidence of a role for protein kinase C. J Biol Chem. 1995;270:28357-28363.
22. DeVore RF, Corbett AH, Osheroff N. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinylamino)methane-sulfon-m-anisidide. Cancer Res. 1992;52:2156-2161.
23. Sahyoun N, Wolf M, Besterman J, et al. Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc Natl Acad Sci U S A. 1986;83:1603-1607.
24. Kawamura K, Grabowski D, Krivacic K, Hidaka H, Ganapathi R. Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium-calmodulin-dependent processes: role for effects on apoptosis, DNA cleavable complex, and phosphorylation. Biochem Pharmacol. 1996;52:1903-1909.
25. Aoyama M, Grabowski DR, Holmes KA, et al. Cell cycle phase specificity in the potentiation of etoposide-induced DNA damage and apoptosis by KN-62, an inhibitor of calcium-calmodulin-dependent enzymes. Biochem Pharmacol. 2001;61:49-54.
26. Grabowski DR, Dubyak GR, Rybicki L, Hidaka H, Ganapathi R. Tumor cell resistance to topoisomerase II poisons: role for intracellular free calcium in the sensitization by inhibitors or calcium-calmodulin-dependent enzymes. Biochem Pharmacol. 1998;56:345-349.
27. Baldwin EL, Osheroff N. Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents. 2005;5:363-372.
28. Rowe TC, Chen GL, Hsiang YH, Liu LF. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res. 1986;46:2021-2026.
29. Chikamori K, Grabowski DR, Kinter M, et al. Phosphorylation of serine 1106 in the catalytic domain of topoisomerase IIα regulates enzymatic activity and drug sensitivity. J Biol Chem. 2003;278:12696-12702.
30. 2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells. J Biol Chem. 2006;281:14026-14040.
31. Bleasdale JE, Thakur NR, Gremban RS, et al. Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther. 1990;255:756-768.
32. Tokumitsu H, Chijiwa T, Hagiwara M, et al. KN-62, 1-[N,O-bis(5- isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II. J Biol Chem. 1990;265:4315-4320.
33. Crivellari D, Veronesi A, Magri MD, et al. Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer. Tumori. 1985;71:499-500.
34. Khafif A, Canfield VA, Syzek EJ, Medina JE. Results of phase I-II trial of concomitant hyperfractionated radiation and oral etoposide (VP-16) in patients with unresectable squamous cell carcinoma of the head and neck. Am J Otolaryngol. 2003;24:1-5.
35. Balan KV, Sitaras NM, Dimas K, et al. Differential susceptibility to etoposide in clones derived from a human ovarian cancer cell line. Chemotherapy. 2006;52:137-146.
36. Chen Y, Su YH, Wang CH, et al. Induction of apoptosis and cell cycle arrest in glioma cells by GL331 (a topoisomerase II inhibitor). Anticancer Res. 2005;25:4203-4208.
37. Ichwan SJ, Yamada S, Sumrejkanchanakij P, Ibrahim-Auerkari E, Eto K, Ikeda MA. Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells. Oncogene. 2006;25:1216-1224.